Indapamida Viatris (Indapamide)

Indapamide inhibits the sodium‑chloride cotransporter in the distal convoluted tubule of the kidney. This reduces reabsorption of sodium and chloride, leading to increased urinary excretion of water and electrolytes, which lowers blood volume and peripheral vascular resistance, thereby decreasing blood pressure and edema.

The appropriate dose of indapamide is determined by the prescribing healthcare professional based on the individual’s clinical condition, response to therapy, and any concomitant medications. Patients should follow the prescriber’s instructions and not adjust the dose on their own.

Safety data for indapamide in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and this decision must be made by a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Indapamide and hydrochlorothiazide belong to the same thiazide‑like class but differ in potency and pharmacokinetic profile. Indapamide often provides a longer duration of action and may have a lower incidence of certain metabolic side effects, while hydrochlorothiazide is widely used and has a well‑established dosing range. Choice of agent depends on patient‑specific factors and prescriber preference.

Store the tablets at ambient temperature, preferably below 25 °C. Keep them in the original blister pack or container, protect from moisture and direct sunlight, and ensure the packaging is tightly closed to maintain product stability.

Indapamida Viatris is taken orally, usually with a full glass of water. It can be taken with or without food, but consistency with respect to meals helps maintain stable absorption. Patients should swallow the tablet whole and not crush or chew it unless instructed otherwise.

Serious risks include severe electrolyte disturbances such as marked hypokalemia or hyponatremia, acute kidney injury manifested by a rapid rise in serum creatinine, and hypersensitivity reactions that may present as rash, angioedema, or severe skin eruptions. Prompt medical attention is required if any of these occur.

Indapamide is contraindicated in patients with anuria, severe renal impairment, or known hypersensitivity to indapamide or other sulfonamide‑derived drugs. Caution is also advised for individuals with gout, severe hepatic disease, or uncontrolled diabetes, and the medication should be avoided in these situations unless a physician determines it is appropriate.